{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:14:42Z","timestamp":1784632482254,"version":"3.55.0"},"reference-count":15,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,9,1]]},"DOI":"10.2169\/internalmedicine.4417-20","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T22:04:44Z","timestamp":1590444284000},"page":"2165-2171","source":"Crossref","is-referenced-by-count":10,"title":["Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD)"],"prefix":"10.2169","volume":"59","author":[{"given":"Yasunobu","family":"Sekiguchi","sequence":"first","affiliation":[{"name":"Department of Hematology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakura","family":"Sakajiri","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Inano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syuichi","family":"Shirane","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Okubo","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Urayasu Sekiguchi Clinic, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Juntendo University Urayasu Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30: 2183-2189, 2012.","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med 378: 331-344, 2018.","DOI":"10.1056\/NEJMc1802363"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ogura M, Tobinai K, Hatake K, et al. Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci 105: 840-846, 2014.","DOI":"10.1111\/cas.12435"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nakazato T, Takanashi S, Hirano M, et al. Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin lymphoma. Ann Hematol 97: 1489-1491, 2018.","DOI":"10.1007\/s00277-018-3279-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Eso Y, Uza N, Shirakawa K, et al. Choledochoduodenal fistula during chemotherapy with brentuximab vedotin for methotrexate-associated lymphoproliferative disorder. Intern Med 57: 2203-2207, 2018.","DOI":"10.2169\/internalmedicine.0557-17"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Vachhani P, Bose N, Brodeur JP, Holkova B, Bose P. Remission of rheumatoid arthritis on brentuximab vedotin. Rheumatology (Oxford) 53: 2314-2315, 2014.","DOI":"10.1093\/rheumatology\/keu374"},{"key":"7","unstructured":"7. Ichikawa S, Fukuhara N, Saito K, et al. Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series. Int J Hematol 111: 667-672, 2020."},{"key":"8","unstructured":"8. Swerdlow SH, Campo E, Pileri SA, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. In: Immunodeficiency-associated lymphoproliferative disorders. revised 4th ed. IARC Publications, 2017: 443-464."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tokuhira M, Watanabe R, Nemoto T, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma 53: 616-623, 2012.","DOI":"10.3109\/10428194.2011.625101"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Momose S, Tamaru JI. Iatrogenic immunodeficiency-associated lymphoproliferative disorders of B-cell type that develop in patients receiving immunosuppressive drugs other than in the post-transplant setting. J Clin Exp Hematop 59: 48-55, 2019.","DOI":"10.3960\/jslrt.19014"},{"key":"11","unstructured":"11. Gion Y, Iwaki N, Takata K, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin lymphoma types. Cancer Sci 108: 1271-1280, 2017."},{"key":"12","unstructured":"12. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91: 20-28, 2013."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tokuhira M, Tamaru JI, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematop 59: 72-92, 2019.","DOI":"10.3960\/jslrt.19007"},{"key":"14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2249.1995.tb03851.x","volume":"102","author":"R Gerli","year":"1995","unstructured":"14. Gerli R, Muscat C, Bistoni O, et al. High levels of the soluble form of CD30 molecule in rheumatoid arthritis (RA) are expression of CD30+ T cell involvement in the inflamed joints. Clin Exp Immunol 102: 547-550, 1995.","journal-title":"Clinical & Experimental Immunology","ISSN":"https:\/\/id.crossref.org\/issn\/0009-9104","issn-type":"print"},{"key":"15","unstructured":"15. Gerli R, Pitzalis C, Bistoni O, et al. CD30+ T cells in rheumatoid synovitis: mechanisms of recruitment and functional role. J Immunol 164: 4399-4407, 2000."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/17\/59_4417-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T03:34:46Z","timestamp":1599276886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/17\/59_4417-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":15,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4417-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,1]]}}}